Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.

Pantuck, Allan J; van Ophoven, Arndt; Gitlitz, Barbara J; Tso, Cho-Lea; Acres, Bruce; Squiban, Patrick; Ross, Michael E; Belldegrun, Arie S; Figlin, Robert A

Pantuck, Allan J; van Ophoven, Arndt; Gitlitz, Barbara J; Tso, Cho-Lea; Acres, Bruce; Squiban, Patrick; Ross, Michael E; Belldegrun, Arie S; Figlin, Robert A.

Affiliation

Pantuck AJ; Department of Urology, David Geffen School of Medicine at University of California, Los Angeles 90095, USA.

J Immunother ; 27(3): 240-53, 2004.

Article in En | MEDLINE | ID: mdl-15076142

Subject(s)

Cancer Vaccines/therapeutic use; Genetic Therapy/methods; Interleukin-2/genetics; Mucin-1/genetics; Prostatic Neoplasms/therapy; Vaccinia virus/genetics; Aged; CD4 Antigens/biosynthesis; CD8 Antigens/biosynthesis; Cell Separation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Flow Cytometry; Genetic Vectors; Humans; Immunotherapy; Interleukin-2/metabolism; Male; Middle Aged; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Th1 Cells; Time Factors; Tumor Necrosis Factor-alpha/metabolism; Up-Regulation

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Vaccinia virus / Genetic Therapy / Interleukin-2 / Mucin-1 / Cancer Vaccines Type of study: Prognostic_studies Limits: Aged / Humans / Male / Middle aged Language: En Journal: J Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2004 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links